Adamas Pharmaceuticals - ADMS Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$8.22
+0 (0.00%)
Get New Adamas Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADMS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADMS

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Adamas Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $8.22.

This chart shows the closing price for ADMS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Adamas Pharmaceuticals. This rating has held steady since November 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings
11/13/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings
2/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings
5/12/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings
8/10/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/8/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/7/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/6/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/17/2021Northland SecuritiesDowngradeOutperform ➝ Market Perform$8.50Low
10/12/2021HC WainwrightDowngradeBuy ➝ Neutral$10.00 ➝ $9.10Low
10/12/2021Piper SandlerDowngradeOverweight ➝ Neutral$7.00 ➝ $8.00Low
10/11/2021SVB LeerinkDowngradeOutperform ➝ Market PerformLow
10/11/2021JMP SecuritiesDowngradeMarket Outperform ➝ Market PerformLow
10/11/2021William BlairDowngradeOutperform ➝ Market PerformHigh
8/27/2021William BlairReiterated RatingBuyLow
8/10/2021HC WainwrightReiterated RatingBuy$10.00High
6/7/2021HC WainwrightBoost TargetBuy$10.00 ➝ $12.00Medium
5/13/2021SVB LeerinkReiterated RatingBuy$6.00High
2/2/2021HC WainwrightBoost TargetBuy$10.00 ➝ $12.00Low
1/28/2021Northland SecuritiesBoost Target$7.50 ➝ $12.50Medium
1/14/2021Needham & Company LLCReiterated RatingHoldLow
8/10/2020William BlairReiterated RatingBuyHigh
8/7/2020Needham & Company LLCReiterated RatingNeutral ➝ HoldHigh
8/7/2020Northland SecuritiesReiterated RatingBuy$7.50High
6/5/2020HC WainwrightReiterated RatingBuy$10.00High
6/5/2020William BlairReiterated RatingBuyHigh
5/8/2020Needham & Company LLCReiterated RatingHoldLow
5/8/2020HC WainwrightReiterated RatingBuy$10.00High
12/18/2019HC WainwrightReiterated RatingBuy$30.00 ➝ $10.00High
12/17/2019Needham & Company LLCReiterated RatingHoldHigh
12/17/2019Cantor FitzgeraldReiterated RatingNeutral$8.00 ➝ $7.00High
12/9/2019Evercore ISIReiterated RatingBuyMedium
12/2/2019HC WainwrightReiterated RatingBuy$30.00High
11/8/2019JMP SecuritiesLower TargetOutperform$16.00High
11/8/2019Needham & Company LLCReiterated RatingHoldHigh
11/8/2019Northland SecuritiesReiterated RatingBuy$15.00High
9/30/2019Bank of AmericaDowngradeNeutral ➝ Underperform$9.00 ➝ $5.00High
9/13/2019Northland SecuritiesSet TargetBuy$15.00Medium
9/9/2019Cantor FitzgeraldInitiated CoverageNeutral$8.00 ➝ $8.00Medium
8/12/2019Evercore ISIReiterated RatingBuy$55.00Medium
8/9/2019CowenSet TargetHold$5.00Medium
5/28/2019HC WainwrightLower TargetBuy$40.00 ➝ $30.00High
4/24/2019MizuhoReiterated RatingSell$5.00Low
3/5/2019Piper Jaffray CompaniesSet TargetBuy$23.00High
3/5/2019HC WainwrightSet TargetBuy$40.00High
3/5/2019Northland SecuritiesReiterated RatingBuy$28.00Low
3/5/2019Needham & Company LLCDowngradeBuy ➝ HoldHigh
3/5/2019CowenDowngradeOutperform ➝ Market Perform$30.00 ➝ $15.00High
3/5/2019MizuhoDowngradeNeutral ➝ Underperform$11.00 ➝ $5.00High
1/14/2019HC WainwrightSet TargetBuy$40.00Low
1/11/2019MizuhoReiterated RatingHold$11.00Medium
11/12/2018SVB LeerinkInitiated CoverageOutperform$20.00Low
11/5/2018HC WainwrightReiterated RatingBuy$40.00High
11/5/2018MizuhoDowngradeBuy ➝ Neutral$75.00 ➝ $18.00High
11/1/2018CowenSet TargetBuy$30.00High
10/19/2018SVB LeerinkReiterated RatingOutperformHigh
10/5/2018Bank of AmericaDowngradeBuy ➝ Neutral$36.00 ➝ $25.00High
9/17/2018HC WainwrightSet TargetBuy$45.00High
8/17/2018MizuhoReiterated RatingBuy$75.00Low
8/6/2018HC WainwrightSet TargetBuy$45.00High
7/16/2018HC WainwrightInitiated CoverageBuy$45.00Medium
4/22/2018Piper Jaffray CompaniesSet TargetBuy$49.00Low
4/20/2018MizuhoReiterated RatingBuy$49.00Medium
4/4/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$31.00High
3/27/2018Bank of AmericaInitiated CoverageBuy$39.00High
2/25/2018Needham & Company LLCSet TargetBuy$40.00Low
2/23/2018Noble FinancialReiterated RatingBuyLow
2/21/2018William BlairReiterated RatingOutperformLow
(Data available from 2/7/2018 forward)

News Sentiment Rating

-0.26 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/12/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/9/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/9/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/8/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/7/2023

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Adamas Pharmaceuticals logo
Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.
Read More

Today's Range

Now: $8.22
Low: $8.22
High: $8.22

50 Day Range

MA: $8.17
Low: $7.97
High: $8.23

52 Week Range

Now: $8.22
Low: $4.02
High: $9.15

Volume

N/A

Average Volume

692,487 shs

Market Capitalization

$376.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.82

Frequently Asked Questions

What sell-side analysts currently cover shares of Adamas Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on Adamas Pharmaceuticals in the last twelve months: StockNews.com.
View the latest analyst ratings for ADMS.

What is the current price target for Adamas Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Adamas Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Adamas Pharmaceuticals in the next year.
View the latest price targets for ADMS.

What is the current consensus analyst rating for Adamas Pharmaceuticals?

Adamas Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ADMS.

What other companies compete with Adamas Pharmaceuticals?

How do I contact Adamas Pharmaceuticals' investor relations team?

Adamas Pharmaceuticals' physical mailing address is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. The specialty pharmaceutical company's listed phone number is (510) 450-3500 and its investor relations email address is [email protected] The official website for Adamas Pharmaceuticals is www.adamaspharma.com. Learn More about contacing Adamas Pharmaceuticals investor relations.